- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving? | 1 | Benzinga.com | ||
| Mi | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever | 337 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining... ► Artikel lesen | |
| Mi | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | Kairos Pharma signs term sheet to acquire lung cancer asset | 3 | Investing.com | ||
| 04.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.05. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | LD Micro: Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI | 499 | Newsfile | Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the... ► Artikel lesen | |
| 08.05. | Kairos Pharma: Interview With Chairman & CEO Dr. John Yu About The Biopharmaceutical Company | 1 | pulse2.com | ||
| 31.03. | Kairos Pharma, LTD. - 10-K, Annual Report | 1 | SEC Filings | ||
| 03.03. | Kairos Pharma signs deal for Celyn Therapeutics' CL-273 | 1 | Pharmaceutical Technology | ||
| 02.03. | Kairos Pharma signs deal to acquire lung cancer drug CL-273 | 1 | Investing.com | ||
| 26.02. | Kairos Pharma, Ltd. gibt Unterzeichnung einer Grundsatzvereinbarung über den strategischen Erwerb von zwei klinischen Onkologie-Assets von Celyn Therapeutics bekannt | 394 | Business Wire | Durch diese transformative Transaktion im Bereich der klinischen Pipeline werden CL-273, ein Pan-EGFR-Inhibitor, und CL-741, ein Phase-1-fähiger c-MET-Inhibitor, in das klinische Portfolio von Kairos... ► Artikel lesen | |
| 26.02. | Kairos Pharma signs term sheet to acquire lung cancer assets | 2 | Investing.com | ||
| 26.02. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.10.25 | Kairos Pharma, Ltd: Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting | 1.032 | Business Wire | Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage... ► Artikel lesen | |
| 07.10.25 | Kairos Pharma, Ltd: Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 | 624 | Business Wire | Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to... ► Artikel lesen | |
| 03.09.25 | Kairos Pharma, Ltd: Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025 | 426 | Business Wire | Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data... ► Artikel lesen | |
| 28.07.25 | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline | 629 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,965 | -0,55 % | Qiagen: Die Gerüchte gehen in die zweite Runde | Im Januar wurde gemunkelt, Qiagen könnte unmittelbar vor einer Übernahme stehen. Doch am Ende verlief die Sache im Sand. Die Aktie, die damals einen Riesensatz nach oben gemacht hatte, fiel tiefer als... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,99 | -0,01 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 19,160 | -0,05 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| TREVI THERAPEUTICS | 19,075 | +0,03 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,500 | -1,58 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,060 | +2,95 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,42 | +2,02 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| KYMERA THERAPEUTICS | 115,77 | +1,56 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,530 | -3,03 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,490 | +3,08 % | Mizuho hebt Kursziel für Tango Therapeutics nach vielversprechenden Studiendaten an | ||
| NURIX THERAPEUTICS | 23,120 | 0,00 % | Mizuho hebt Kursziel für Nurix nach Roche-Deal auf 34 US-Dollar an | ||
| ARRIVENT BIOPHARMA | 33,190 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,960 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| CG ONCOLOGY | 71,92 | +3,48 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 42,620 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP-... ► Artikel lesen |
Das Unternehmen KAIROS PHARMA LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,024 (-7,12 %) liegt der Kurs bei 0,316 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.